Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16 PASADENA, Calif. — March 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today
ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS PASADENA, Calif. – February 10, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal
Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference PASADENA, Calif. — February 9, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR ), a nanomedicine company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO
Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011 PASADENA, Calif. — February 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a focused nanomedicine holding company, today announced that it will report its
Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a
Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals PASADENA, Calif. – January 18, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted